Join Now
Sign In
Paul Hendrie, MD, PhD
PaulHendrieMDPhD (Physician - Oncology - Hematology/Oncology (Verified) )| Communities: Non-Hodgkin Lymphoma , CLL (Chronic Lymphocytic Leukemia) , Hodgkin Lymphoma , Myeloma | Answers: 8 |
| Member Since: Jun. 2012 |
Ask PaulHendrieMDPhD a question:
0
Cc:
Twitter
Facebook
Professional Statement
Dr. Hendrie is a hematology specialist who treats patients for blood disorders, leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome. He is also Acting Instructor in the Hematology Division at University of Washington School of Medicine.
Professional Info
Credential: MD
Primary specialty: Oncology - Hematology/Oncology
Medical school: Indiana University School of Medicine
Residency: Indiana University School of Medicine
Fellowship: University of Washington Hematology
Areas of expertise: General non-malignant hematologic conditions including cytopenias, clotting disorders and porphyrias. Myelodysplastic syndrome. Chronic myeloproliferative disorders, including PV, ET, MM and CML. Chronic lymphoproliferative disorders including CLL. Other malignant hematologic conditions.
Hospital affiliation: Seattle Cancer Care Alliance
Practice address:
825 Eastlake Ave. E, P.O. Box 19023
Seattle, WA
98109-1023
Practice phone number: (206) 288-SCCA (7222)
PaulHendrieMDPhD Activities
Monoclonal antibody treatments are chosen based on the presence of the targeted protein on the CLL cell and proven clinical effectiveness. The monoclonal antibody Rituxan targets the lymphocyte protein CD20 and has proven activity against CLL when tested in clinical trials. Rituxan, although it has activity against CLL when used alone, is usually used in combination with one or two other chemotherapy drugs for best effect. Rituxan is commonly used because of both its effectiveness and because it is well tolerated with relatively few side effects. Rituxan is used with caution when patients have very high white blood counts. When large numbers of cells are exposed to the antibody, substances are released that can cause fevers, low blood pressure, and other effects on the body that can be uncomfortable and sometimes dangerous. This problem can often be lessened by giving another chemotherapy drug prior to the Rituxan. With repeated exposures, CLL cells become resistant to Rituxan and other treatments need to be chosen. Both Campath and ofatumumab can be used to treat patients whose CLL cells are unresponsive to Rituxan.
New answer by PaulHendrieMDPhD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
Rituxan (rituximab) is a monoclonal antibody against the common protein on B-lymphocytes called CD20. A second monoclonal antibody against CD20 is also now available called Ofatumumab. Campath (alemtuzumab) is an antibody to the protein CD 52 found on lymphocytes and CLL cells.
New answer by PaulHendrieMDPhD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
Monitoring schedules for patients with CLL depends on the rate of change of their disease. Some patients with low white blood counts and no lymphadenopathy can be seen in clinic annually. Whereas, patients with high white counts, particularly white counts that are rising, need to be monitored more frequently, maybe every 3 months. In general, monitoring early stage CLL involved physical exams and blood work for white blood count, hematocrit and platelet count. Routine bone marrow biopsies and CT scans are not needed unless there are changes in symptoms, exam or blood counts.
New answer by PaulHendrieMDPhD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
Watchful waiting is the recommend approach to patients with early stage chronic lymphocytic leukemia, because some patients can go many years before progression and the treatments we have right now are effective for producing remissions but rarely complete cures. Watching waiting is recommended for patient’s without anemia or low platelet counts, without bulky lymphadenopathy, and without symptoms such as fevers, night sweats and weight loss. A very rapid rise in the abnormal lymphocyte count is also an indication to treat not wait.
New answer by PaulHendrieMDPhD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
I do not have any specific comments on the Vaxil trial. Cancer vaccines are an exciting future treatment option and I encourage participation in these ongoing clinical trials. Vaccines may be best used when there is low disease burden.
New answer by PaulHendrieMDPhD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
The myelodysplastic syndromes are in a spectrum with acute myeloid leukemia depending on the percentage of the blasts in the blood and marrow. The diagnosis of leukemia arbitrarily requires a diagnosis of 20%. Most patient who die of MDS, do not progress to acute leukemia but rather die of complications of low blood counts. Only bone marrow transplantation cures patients with MDS.
New answer by PaulHendrieMDPhD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
The 5 year survival rate after bone marrow transplantation for acute lymphoblastic leukemia is around 40%. The relapse rate is 13 to 26%. These rates can depend on the subtypes of leukemia and the variables of the transplant including the chemotherapy, immune suppression, and donor.
New answer by PaulHendrieMDPhD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
The terms sticky platelets or clumpy platelets can be used in a variety of conditions, but most commonly they refer to the platelets that stick together or form clumps after they are removed from the body.
This can result falsely low platelet counts from automated cell counters. It is usually caused by a protein the binds to a surface of the platelets only when the platelets are in EDTA, the common stabilizing solution in the test tube. Sometimes blood can be drawn in citrate to correct this problem. The platelets are not clumped in the body, so they do not cause any harm.
This can result falsely low platelet counts from automated cell counters. It is usually caused by a protein the binds to a surface of the platelets only when the platelets are in EDTA, the common stabilizing solution in the test tube. Sometimes blood can be drawn in citrate to correct this problem. The platelets are not clumped in the body, so they do not cause any harm.
New answer by PaulHendrieMDPhD (Physician - Oncology - Hematology/Oncology (Verified))
1
Answer |
9 months ago
PaulHendrieMDPhD's Profile
Newsletters
Sign up for email updates of the latest news, best answers, and featured experts.
Benefits
Custom health, wellness, & medical offers including clinical trials, market research opportunities, & new programs.
Share TalkAboutHealth
To share TalkAboutHealth with friends, type their email addresses here (separated by commas):
From:
Add a personal note here:
Please join TalkAboutHealth and you will be able to ask questions.
Your question to PaulHendrieMDPhD:
2) Background Info (optional): What context or background information is relevant to this request?
Notes:
The more clear and thorough your request, the more likely you will receive support.
Many of our members are learning from this information or english might not be their first language. Please use standard english and spell out all words. For example, use 'you' instead of 'u'.
The more clear and thorough your request, the more likely you will receive support.
Many of our members are learning from this information or english might not be their first language. Please use standard english and spell out all words. For example, use 'you' instead of 'u'.
Newsletters
